Non-selective inhibitors of both PDGFR-beta and PDGFR-alpha, such as imatinib and dasatinib, are known to partially inhibit melanoma growth, but the role of the alpha or beta receptors has not been fully clarified yet [41–43]. This evidence concerns the gene PDGFRA and melanoma.